Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

The Muscular Dystrophy Association celebrates this new more accessible treatment option for people living with SMA. MDA - New ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

multiple sclerosis (MS), spinal muscular atrophy (SMA), and amyotrophic lateral sclerosis (ALS). On January 26, Eisai Co., Ltd. and Biogen announced that the U.S. Food and Drug Administration (FDA ...

The announcement was made by Stephanie Fradette, Pharm.D., Head of the Neuromuscular Development Unit at Biogen, who expressed gratitude to the SMA community for their support. The DEVOTE study ...

Biogen's officials expressed optimism about the potential benefits this regimen could offer to SMA patients and their families. The DEVOTE study, which evaluated the higher dose regimen's safety ...

The FDA and EMA have both accepted Biogen’s applications for a higher dose regimen of Spinraza (nusinerse) for spinal muscular atrophy (SMA). According to the company, the regimen includes a faster ...

(RTTNews) - Biogen Inc. (BIIB) announced Thursday that ... a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen comprises a more rapid ...